{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:38:14Z","timestamp":1761824294294,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.yebeh.2021.107975","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T18:58:38Z","timestamp":1619895518000},"page":"107975","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9446-0400","authenticated-orcid":false,"given":"Kia H.","family":"Markussen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica K.A.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Mach\u00edo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Dolce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. Paul","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig W.","family":"Vander Kooi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5253-9049","authenticated-orcid":false,"given":"Matthew S.","family":"Gentry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.yebeh.2021.107975_b0005","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.R117.803064","article-title":"Lafora disease offers a unique window into neuronal glycogen metabolism","volume":"293","author":"Gentry","year":"2018","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.yebeh.2021.107975_b0010","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41582-018-0057-0","article-title":"Lafora disease - from pathogenesis to treatment strategies","volume":"14","author":"Nitschke","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.yebeh.2021.107975_b0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.yebeh.2017.12.015","article-title":"The 3rd International Lafora Epilepsy Workshop: Evidence for a cure","volume":"81","author":"Brewer","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107975_b0020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.yebeh.2018.11.014","article-title":"The 4th International Lafora Epilepsy Workshop: Shifting paradigms, paths to treatment, and hope for patients","volume":"90","author":"Brewer","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.107975_b0025","doi-asserted-by":"crossref","first-page":"106839","DOI":"10.1016\/j.yebeh.2019.106839","article-title":"The 5th International Lafora Epilepsy Workshop: Basic science elucidating therapeutic options and preparing for therapies in the clinic","volume":"103","author":"Gentry","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"10","key":"10.1016\/j.yebeh.2021.107975_b0030","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107975_b0035","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1056\/NEJMoa1710504","article-title":"Nusinersen versus sham control in later-onset spinal muscular atrophy","volume":"378","author":"Mercuri","year":"2018","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.yebeh.2021.107975_b0040","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107975_b0045","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1002\/ehf2.13154","article-title":"Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data","volume":"8","author":"Viney","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"8","key":"10.1016\/j.yebeh.2021.107975_b0050","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nbt.3589","article-title":"Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames","volume":"34","author":"Liang","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107975_b0055","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yebeh.2021.107975_b0060","doi-asserted-by":"crossref","unstructured":"Ahonen S, Nitschke S, Grossman TR, Kordasiewicz H, Wang P, Zhao X, et al. Gys1 antisense therapy rescues neuropathological bases of murine Lafora disease. 2021.","DOI":"10.1101\/2021.02.11.430846"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107975_b0065","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/WNR.0000000000000751","article-title":"4-Phenylbutyric acid and metformin decrease sensitivity to pentylenetetrazol-induced seizures in a malin knockout model of Lafora disease","volume":"28","author":"S\u00e1nchez-Elexpuru","year":"2017","journal-title":"NeuroReport"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107975_b0070","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s12035-015-9091-8","article-title":"Pharmacological interventions to ameliorate neuropathological symptoms in a mouse model of Lafora disease","volume":"53","author":"Berthier","year":"2016","journal-title":"Mol Neurobiol"},{"issue":"3","key":"10.1016\/j.yebeh.2021.107975_b0075","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s12035-019-01842-z","article-title":"Reactive glia-derived neuroinflammation: a novel hallmark in Lafora progressive myoclonus epilepsy that progresses with age","volume":"57","author":"Lahuerta","year":"2020","journal-title":"Mol Neurobiol"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107975_b0080","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/can.2019.0005","article-title":"Cannabidiol-enriched extract reduced the cognitive impairment but not the epileptic seizures in a Lafora disease animal model","volume":"5","author":"Aso","year":"2020","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.yebeh.2021.107975_b0085","doi-asserted-by":"crossref","DOI":"10.1007\/s12035-021-02285-1","article-title":"Modulators of neuroinflammation have a beneficial effect in a Lafora disease mouse model","author":"Molla","year":"2021","journal-title":"Mol Neurobiol"},{"issue":"7356","key":"10.1016\/j.yebeh.2021.107975_b0090","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nature10317","article-title":"Molecular chaperones in protein folding and proteostasis","volume":"475","author":"Hartl","year":"2011","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107975_b0095","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.arr.2010.02.001","article-title":"Protein homeostasis and aging: The importance of exquisite quality control","volume":"10","author":"Koga","year":"2011","journal-title":"Ageing Res Rev"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107975_b0100","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cell.2011.07.030","article-title":"Autophagy and aging","volume":"146","author":"Rubinsztein","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.yebeh.2021.107975_b0105","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.ajpath.2011.11.012","article-title":"Decreased proteasomal activity causes age-related phenotypes and promotes the development of metabolic abnormalities","volume":"180","author":"Tomaru","year":"2012","journal-title":"Am J Pathol"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107975_b0110","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"L\u00f3pez-Ot\u00edn","year":"2013","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107975_b0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrneurol.2010.178","article-title":"The role of inflammation in epilepsy","volume":"7","author":"Vezzani","year":"2011","journal-title":"Nat Rev Neurol"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107975_b0120","doi-asserted-by":"crossref","first-page":"614","DOI":"10.4161\/auto.6.5.12189","article-title":"Keap1 facilitates p62-mediated ubiquitin aggregate clearance via autophagy","volume":"6","author":"Fan","year":"2010","journal-title":"Autophagy"},{"key":"10.1016\/j.yebeh.2021.107975_b0125","doi-asserted-by":"crossref","unstructured":"Aguado C, Sarkar S, Korolchuk VI, Criado O, Vernia S, Boya P, et al. Laforin, the most common protein mutated in Lafora disease, regulates autophagy. Hum Mol Genet. 2010;19(14):2867-76.","DOI":"10.1093\/hmg\/ddq190"},{"key":"10.1016\/j.yebeh.2021.107975_b0130","doi-asserted-by":"crossref","unstructured":"Criado O, Aguado C, Gayarre J, Duran-Trio L, Garcia-Cabrero AM, Vernia S, et al. Lafora bodies and neurological defects in malin-deficient mice correlate with impaired autophagy. Hum Mol Genet. 2012;21(7):1521-33.","DOI":"10.1093\/hmg\/ddr590"},{"key":"10.1016\/j.yebeh.2021.107975_b0135","doi-asserted-by":"crossref","unstructured":"Turnbull J, DePaoli-Roach AA, Zhao X, Cortez MA, Pencea N, Tiberia E, et al. PTG depletion removes Lafora bodies and rescues the fatal epilepsy of Lafora disease. PLoS Genet. 2011;7(4):e1002037.","DOI":"10.1371\/journal.pgen.1002037"},{"issue":"3","key":"10.1016\/j.yebeh.2021.107975_b0140","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/ana.24104","article-title":"PTG protein depletion rescues malin-deficient Lafora disease in mouse","volume":"75","author":"Turnbull","year":"2014","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.yebeh.2021.107975_b0145","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/hmg\/ddu024","article-title":"Glycogen accumulation underlies neurodegeneration and autophagy impairment in Lafora disease","volume":"23","author":"Duran","year":"2014","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.yebeh.2021.107975_b0150","doi-asserted-by":"crossref","first-page":"105173","DOI":"10.1016\/j.nbd.2020.105173","article-title":"Suppression of glycogen synthesis as a treatment for Lafora disease: Establishing the window of opportunity","volume":"147","author":"Varea","year":"2021","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.yebeh.2021.107975_b0155","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.015773","article-title":"An inducible glycogen synthase-1 knockout halts but does not reverse Lafora disease progression in mice","author":"Nitschke","year":"2021","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.yebeh.2021.107975_b0160","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1021\/acs.jmedchem.9b01851","article-title":"Discovery and development of small-molecule inhibitors of glycogen synthase","volume":"63","author":"Tang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.yebeh.2021.107975_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.07.002","article-title":"Targeting pathogenic Lafora bodies in Lafora disease using an antibody-enzyme fusion","author":"Brewer","year":"2019","journal-title":"Cell Metab"},{"issue":"9","key":"10.1016\/j.yebeh.2021.107975_b0170","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1021\/acs.molpharmaceut.9b00396","article-title":"Central nervous system delivery and biodistribution analysis of an antibody-enzyme fusion for the treatment of Lafora disease","volume":"16","author":"Austin","year":"2019","journal-title":"Mol Pharm"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:39:40Z","timestamp":1761503980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021002092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":34,"alternative-id":["S1525505021002092"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107975","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The 6th International Lafora Epilepsy Workshop: Advances in the search for a cure","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107975","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107975"}}